-- AbbVie (ABBV) partner EvolveImmune Therapeutics has nominated a development candidate for a next-generation cancer biotherapeutic, triggering a preclinical milestone payment of $18 million from AbbVie, the immuno-oncology company said Tuesday.
The two companies entered into a collaboration and option-to-license agreement to develop multi-specific biologics for multiple targets in oncology in October 2024, according to a statement.
Price: $198.10, Change: $+0.72, Percent Change: +0.37%